All In Biotech

Drug Trial Radar · NCT06282159

A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

A Phase 2, Randomized, Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

65

Actual

Start

Feb 23, 2024

Primary completion

Jul 28, 2025

Study completion Oct 2028

Sponsor

Lead sponsor
Dianthus TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with generalized myasthenia gravis (gMG).

Conditions

  • Myasthenia Gravis, Generalized

Interventions

  • ClaseprubartDrug

    Day 1: IV loading dose Week 1 to Week 11: Claseprubart administered SC every 2 weeks

  • PlaceboDrug

    Day 1: IV infusion of placebo Week 1 to Week 11: placebo administered SC every 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)Time frame: Baseline (Day 1) to Week 13

Locations

56 sites in 14 countries. Site status is shown where the registry gives one.

  • Clinical Study Site

    Phoenix, Arizona

  • Clinical Study Site

    Irvine, California

  • Clinical Study Site

    Stamford, Connecticut

  • Clinical Study Site

    Boca Raton, Florida

  • Clinical Study Site

    Bradenton, Florida

  • Clinical Study Site

    Maitland, Florida

  • Clincal Study Site

    Tampa, Florida

  • Clinical Study Site

    O'Fallon, Illinois

  • Clinical Study Site

    Kansas City, Kansas

  • Clinical Study Site

    Lexington, Kentucky

  • Clinical Study Site

    Boston, Massachusetts

  • Clinical Study Site

    East Lansing, Michigan

  • Clinical Study Site

    Columbia, Missouri

  • Clinical Study Site

    Cincinnati, Ohio

  • Clinical Study Site

    Columbus, Ohio

  • Clinical Study Site

    Dallas, Texas

  • Clinical Study Site

    Dallas, Texas

  • Clinical Study Site #2

    Houston, Texas

  • Clinical Study Site

    Houston, Texas

  • Clinical Study Site

    Lubbock, Texas

  • Clinical Study Site

    Richmond, Virginia

  • Clinical Study Site

    Buenos Aires, Argentina

  • Clinical Study Site

    Buenos Aires, Argentina

  • Clinical Study Site

    Buenos Aires, Argentina

  • Clinical Study Site

    Córdoba, Argentina

  • Clinical Study Site

    Rosario, Argentina

  • Clinical Study Site

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Clinical Study Site

    London, Ontario, Canada

  • Clinical Study Site

    Ostrava, Czechia

  • Clinical Study Site

    Copenhagen, Denmark

  • Clinical Study Site

    Bordeaux, France

  • Clinical Study Site

    Nice, France

  • Clinical Study Site

    Strasbourg, France

  • Clinical Study Site

    Haifa, Israel

  • Clinical Study Site

    Ramat Gan, Israel

  • Clinical Study Site

    Safed, Israel

  • Clinical Study Site

    Milan, Italy

  • Clinical Study Site

    Naples, Italy

  • Clinical Study Site

    Pisa, Italy

  • Clinical Study Site

    Rome, Italy

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.